Nuvectis Pharma spent its public life as a single-asset oncology shop built around NXP900, an oral inhibitor of the SRC family of kinases. Mid-year the company bought a different identity. An exclusive license with Haisco Pharmaceutical Group brought two clinical-stage assets, and the lead is now ciprocopan, a once-daily oral Factor B inhibitor already approved in China for treatment-naive paroxysmal nocturnal hemoglobinuria. The equity stopped being an early combination-stage kinase option and started being a late-stage complement story that still has no United States investigational application on file.
The license cost a $20 million upfront plus up to $20 million of near-term development milestones. Contingent payments can reach another $1.4 billion, plus high-single to mid-teen royalties. A July follow-on sold stock at $20 a share. Gross proceeds were $115 million. That haul is enough for management to talk about runway into early 2029 after the Haisco check. Quarter-end cash was only $22 million, so the printed balance sheet is the pre-deal stub. What the market is buying is not that stub. It is the probability that Chinese superiority data versus eculizumab can be converted into a Western development path without a full new registrational program.
Second-quarter net loss widened only modestly, to $7 million, because the Haisco assets were not yet on the books. Research spending rose as manufacturing and trial costs for the old kinase program stepped up, while overhead actually fell. The next test is not another earnings print. It is whether the Food and Drug Administration treats the China package as a foundation or as a foreign experiment that has to be repeated. That single regulatory conversation decides if today's enterprise value is a late-stage franchise or an expensive option on someone else's data.